Literature DB >> 9403210

Membranoproliferative glomerulonephritis induced by portosystemic shunt surgery for non-cirrhotic portal hypertension.

J Soma1, T Saito, H Sato, T Ootaka, K Abe.   

Abstract

The liver and spleen both have important phagocytic functions and contain monocytes/macrophages which clear immune complexes. We describe here three patients who presented proteinuria and hematuria 7 to 13 years after portosystemic shunt surgery, which diverted portal venous blood to the systemic circulation. They had hematemesis and/or melena and underwent mesocaval shunt surgery and splenectomy in childhood because of non-cirrhotic portal hypertension with esophageal varices. Renal biopsy specimens revealed findings characteristic of membranoproliferative glomerulonephritis (MPGN) type I. Immunohistologically, these three cases were accompanied by a distinct IgA deposition along with a marked C3 deposition. The IgA observed in these three cases contained not only IgA1 but also IgA2, which is the predominant form of mucosal IgA. On the other hand, of 20 patients with idiopathic MPGN type I with IgA deposition (n = 20), only two were positive for IgA2, and the distribution was focal and segmental. Our study shows that MPGN type I may have developed secondary to portosystemic shunt. This secondary form of MPGN type I may be caused by a reduced clearance of immune complexes in the liver and their deposition in the glomerulus, since a portosystemic shunt routes portal venous blood from the intestinal tract directly to the systemic circulation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9403210

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  7 in total

1.  Noncirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and treatment.

Authors:  Shiv Kumar Sarin; Ashish Kumar; Yogesh Kumar Chawla; Sanjay Saran Baijal; Radha Krishna Dhiman; Wasim Jafri; Laurentius A Lesmana; Debendranath Guha Mazumder; Masao Omata; Huma Qureshi; Rizvi Moattar Raza; Peush Sahni; Puja Sakhuja; Mohammad Salih; Amal Santra; Barjesh Chander Sharma; Praveen Sharma; Gamal Shiha; Jose Sollano
Journal:  Hepatol Int       Date:  2007-09-11       Impact factor: 6.047

2.  Immune Complex Membranoproliferative Glomerulonephritis Associated with Transjugular Intrahepatic Portosystemic Shunts in Alcoholic Cirrhosis: Two Case Reports.

Authors:  Julio Hernández-Jaras; Jordi Espí-Reig; Rafael Alis; Ana-Maria García-Martínez; Diego Rodríguez-Ortega; Lourdes Roca-Argente; Jose-Luis Moll-Guillen
Journal:  Med Princ Pract       Date:  2017-02-22       Impact factor: 1.927

3.  Remission of membranoproliferative glomerulonephritis associated with a noncirrhotic portosystemic shunt after percutaneous transhepatic portal vein embolization.

Authors:  Nobuhiko Okamoto; Sawako Fukazawa; Masafumi Shimamoto; Rie Yamamoto; Yuichiro Fukazawa
Journal:  NDT Plus       Date:  2009-02-16

4.  IgA nephropathy featuring massive wire loop-like deposits in two patients with alcoholic cirrhosis.

Authors:  Daisuke Takada; Keiichi Sumida; Akinari Sekine; Ryo Hazue; Masayuki Yamanouchi; Tatsuya Suwabe; Noriko Hayami; Junichi Hoshino; Naoki Sawa; Kenmei Takaichi; Takeshi Fujii; Kenichi Ohashi; Yoshifumi Ubara
Journal:  BMC Nephrol       Date:  2017-12-13       Impact factor: 2.388

5.  Case Report: Membranoproliferative Glomerulonephritis, a Rare Clinical Manifestation of Abernethy Malformation Type II.

Authors:  Xue He; Yueling Zhu; Haidong Fu; Chunyue Feng; Zhixia Liu; Weizhong Gu; Yanyan Jin; Binbin Yang; Huijun Shen
Journal:  Front Pediatr       Date:  2021-03-17       Impact factor: 3.418

Review 6.  Presentation of Congenital Portosystemic Shunts in Children.

Authors:  Atessa Bahadori; Beatrice Kuhlmann; Dominique Debray; Stephanie Franchi-Abella; Julie Wacker; Maurice Beghetti; Barbara E Wildhaber; Valérie Anne McLin
Journal:  Children (Basel)       Date:  2022-02-11

7.  Membranoproliferative glomerulonephritis and inflammatory pseudotumour of the spleen.

Authors:  U Hadimeri; P Hultman; R Larsson; S Melander; J Mölne; H Hadimeri
Journal:  Case Rep Oncol       Date:  2013-02-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.